Head-to-head · WeighScore
HealthSource vs REMEVi
By GLP-1 ScorecardUpdated
Score comparison
REMEVi has the higher recorded score — 73.5/100 to 71.2/100.
REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | HealthSource | REMEVi |
|---|---|---|
| WeighScore | 71.2/100 | 73.5/100 |
| Grade | C | C |
| Site position | #105 | #78 |
| Semaglutide | $199/mo (all doses, compounded) | $219/mo |
| Tirzepatide | $299/mo (all doses, compounded) | $319/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #105 · C
Strengths
- Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
- 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
- Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
- Subscription auto-refund if monthly reassessment is not completed
- Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping
What to consider
- No physician names or clinical leadership disclosed on public pages
- No LegitScript certification found
- 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
- Labs not mentioned on any product page — baseline bloodwork protocol unknown
- WooCommerce e-commerce storefront may feel more transactional than clinical
Site position #78 · C
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
What to consider
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.